Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn’s disease

1

Isoniazid is commonly used as a prophylactic treatment for latent tuberculosis in patients receiving anti-TNF therapy.
2

This study investigates Isoniazid's potential as a TB-independent therapeutic option for Crohn's disease-like ileitis.
3

Isoniazid administration significantly reduces systemic and intestinal inflammation in a TNFΔARE mouse model.
4

The drug limits the expansion of pathobionts like segmented filamentous bacteria, which are linked to intestinal inflammation.
5

Isoniazid's protective effects may involve altering cytokine decay and reducing the formation of ectopic tertiary lymphoid organs.

Journal Of Crohn's And Colitis

by Matthew Stephens, Keith Keane, Simon Roizes, Manon Defaye, Christophe Altier, Pierre-Yves von der Weid
February 23, 2025

1